Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era

被引：3
|
作者：
Liang, Xiping [1 ]
Hu, Renzhi [1 ]
Li, Qiying [1 ]
Wang, Chaoyu [1 ]
Liu, Yao [1 ]
机构：
[1] Chongqing Univ, Dept Hematol Oncol, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY | 2023年 / 122卷
关键词：
NCCN-IPI; EXPRESSION; CLASSIFICATION; BIOMARKER; SURVIVAL; ACCURATE; SUBTYPES; MARKER; DNA;
D O I：
10.1016/j.exphem.2023.03.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 9
页数：9
相关论文
共 50 条
  • [21] A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors
    Yuan, Tingting
    Chen, Xuetao
    Zhang, Yuewei
    Wei, Maomao
    Zhu, Hua
    Yang, Zhi
    Wang, Xuejuan
    NUCLEAR MEDICINE COMMUNICATIONS, 2023, 44 (07) : 622 - 630
  • [22] Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht, Christian
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2012, : 410 - 416
  • [23] Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era
    Mounier, Nicolas
    Gisselbrecht, Christian
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) : 209 - 213
  • [24] Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era
    Kumar, Anita
    Lunning, Matthew A.
    Zhang, Zhigang
    Migliacci, Jocelyn C.
    Moskowitz, Craig H.
    Zelenetz, Andrew D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) : 776 - 783
  • [25] Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results
    Adiyaman, Suleyman Cem
    Alacacioglu, Inci
    Danyeli, Ayca Ersen
    Turkyilmaz, Dogus
    Sevindik, Omur Gokmen
    Demirkan, Fatih
    Piskin, Ozden
    Ozcan, Mehmet Ali
    Undar, Bulent
    Ozkal, Sermin
    Ozsan, Guner Hayri
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (02) : 81 - 87
  • [26] A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study
    Cai, Jun
    Tian, Xiaopeng
    Ma, Shuyun
    Zhong, Liye
    Li, Wenyu
    Wang, Liang
    Guo, Linlang
    Li, Zhihua
    Wu, Yudan
    Zhong, Guangzheng
    Huang, Huiqiang
    Xia, Zhongjun
    Xia, Yi
    Liu, Panpan
    Su, Ning
    Fang, Yu
    Zhang, Yuchen
    Cai, Qingqing
    BRITISH JOURNAL OF CANCER, 2021, 125 (03) : 402 - 412
  • [27] An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
    Zhou, Zheng
    Sehn, Laurie H.
    Rademaker, Alfred W.
    Gordon, Leo I.
    LaCasce, Ann S.
    Crosby-Thompson, Allison
    Vanderplas, Ann
    Zelenetz, Andrew D.
    Abel, Gregory A.
    Rodriguez, Maria A.
    Nademanee, Auayporn
    Kaminski, Mark S.
    Czuczman, Myron S.
    Millenson, Michael
    Niland, Joyce
    Gascoyne, Randy D.
    Connors, Joseph M.
    Friedberg, Jonathan W.
    Winter, Jane N.
    BLOOD, 2014, 123 (06) : 837 - 842
  • [28] Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases
    Gorodetskiy, Vadim
    Probatova, Natalya
    Obukhova, Tatiana
    Vasilyev, Vladimir
    LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
  • [29] The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma
    Yang, Yan
    Wang, Lanlan
    Ma, Yanna
    Han, Tingting
    Huang, Mei
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 353 (05) : 459 - 465
  • [30] The Prognostic Importance of Immunohistochemical Biomarkers in Diffuse Large B-Cell Lymphoma
    Korkmaz, S.
    Sencan, M.
    Yildiz, E.
    Terzi, H.
    Egilmez, R.
    WEST INDIAN MEDICAL JOURNAL, 2021, 69 (01) : 38 - 43
12345